Change Password!
Reset Password!
Oral solution of dispersible nano cannabidiol offers fast-acting relief which can be useful for a range of psychiatric disorders, either as monotherapy or alongside other medications.
About 301 million people throughout the world are affected by anxiety disorders but there is a lack of therapies with quick onset of action and minimal side effects. A recent study led by Prasad Rao Gundugurti and published in the Asian Journal of Psychiatry investigated the efficacy and safety of cannabidiol (CBD) versus placebo in hopes of meeting this need.
In this trial, 178 participants were randomized with 89 receiving CBD and the other 89 receiving placebo. Oral solution of CBD 150 mg per mL showed significant promise in treating anxiety disorders compared to a placebo. Those who received CBD experienced a notable decrease in generalized anxiety disorder (GAD)-7 scores and Hamilton Anxiety Rating Scale (HAM-A) scores from baseline, demonstrating its effectiveness. These results fulfilled both the primary and secondary study goals (clinical global impression (CGI) rating scales along with Patient Health Questionnaire and Pittsburgh Sleep Quality Index scores), indicating CBD's potential as a therapeutic option for anxiety, depression, and sleep quality issues.
Nano-dispersible CBD has emerged as a safe, well-tolerated, and effective remedy for mild to moderate anxiety disorders, offering relief from associated depression and sleep disturbances without any serious adverse effects.
Asian Journal of Psychiatry
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial
Prasad Rao Gundugurti et al.
Comments (0)